Filament Health Corp. (FLHLF)
| Previous close | 0.0377 |
| Open | 0.0374 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0374 - 0.0374 |
| 52-week range | 0.0320 - 0.2010 |
| Volume | |
| Avg. volume | 18,744 |
| Market cap | 7.899M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector • The Cannabist Company celebrated approval for adult-use cannabis sales in New York. • Curaleaf gained conditional approval for uplisting to the Toronto Stock Exchange. • MedMen prevailed in legal battle against Whitestar Solutions allegations. Key Takeaways; Psychedelic Sector • Awakn received regulatory and ethical approval for Phase III clinical trial […]
GlobeNewswirePharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules
Filament Health and PharmAla Biotech also completed shipments to a number of Australian clientsVANCOUVER, British Columbia, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA)(OTCQB:PMBHF), a Canadian biotechnology company dedicated to the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds, and Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, today
